How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study-Reference-Cited by-同舟云学术

How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study

Published:2019-04 Issue:4 Volume:21 Page:968-974
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Birkeland Kåre I.¹^ORCID,Bodegard Johan²^ORCID,Norhammar Anna³^ORCID,Kuiper Josephina G.⁴,Georgiado Elena⁵,Beekman‐Hendriks Wendy L.⁶,Thuresson Marcus⁷,Pignot Marc⁸,Herings Ron M. C.⁴⁹,Kooy Adriaan¹⁰^ORCID

Affiliation:

1. Department of Transplantation Medicine, Division of Surgery, Inflammatory Medicine and TransplantationOslo University Hospital and University of Oslo Oslo Norway

2. AstraZeneca Nordic‐Baltic Oslo Norway

3. Karolinska InstitutetKarolinska University Hospital Stockholm Sweden

4. PHARMO Institute for Drug Outcomes Research Utrecht The Netherlands

5. Team Gesundheit GmbH Essen Germany

6. AstraZeneca Den Haag The Netherlands

7. Statisticon AB Uppsala Sweden

8. Kantar Health GmbH Munich Germany

9. Department of Epidemiology and BiostatisticsVU University Medical Center Amsterdam The Netherlands

10. University Medical Center Groningen and Bethesda Diabetes Research Center Hoogeveen Groningen The Netherlands

Funder

AstraZeneca

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.13612

Reference26 articles.

1. Incidence, prevalence and mortality of type 2 diabetes requiring glucose-lowering treatment, and associated risks of cardiovascular complications: a nationwide study in Sweden, 2006–2013

2. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta‐analysis of cardiovascular outcome trials;Zelniker TA;Lancet.,2018

3. Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV)

4. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

5. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preclinical modeling of metabolic syndrome to study the pleiotropic effects of novel antidiabetic therapy independent of obesity;Scientific Reports;2024-09-05

2. Generalizability and treatment with sodium-glucose co-trasporter-2 inhibitors (SGLT2i) among patients with type 2 diabetes: an assessment using an Italian primary care database;Acta Diabetologica;2024-08-29

3. Key results from observational studies and real‐world evidence of sodium‐glucose cotransporter‐2 inhibitor effectiveness and safety in reducing cardio‐renal risk;Diabetes, Obesity and Metabolism;2024-06-10

4. Preclinical Modeling of Metabolic Syndrome to Study the Pleiotropic Effects of Novel Antidiabetic Therapy Independent of Obesity;2024-04-22

5. Prevalence of heart failure among hospitalized patient with T2D: results of a prospective observational multicenter study (CREDO);Diabetes mellitus;2024-03-18